CSPC Pharmaceutical Group's SYS6041 Combination Therapy Phase II Trial for Recurrent Ovarian Cancer Has Officially Launched at the First Center in China

Stock News07-31

CSPC PHARMA (01093) has announced that the Phase II clinical trial for its SYS6041 (the product) in combination therapy to treat recurrent ovarian cancer has officially launched at the first center in China. The product is an antibody-drug conjugate targeting folate receptor alpha (FRα), classified as a Class 1 therapeutic biological product.

The antibody of this product can specifically bind to the surface of cells expressing FRα and be internalized into the cells' lysosomes. There, it is specifically cleaved by cathepsins to release a small molecule toxin—a topoisomerase I inhibitor—thereby killing tumor cells. Additionally, the product can nonspecifically clear surrounding tumor cells through the bystander effect.

Previously, the company received the Phase II clinical trial approval notice for combination therapy from the National Medical Products Administration in June 2026. The clinical trial is now underway, aiming to evaluate the safety, tolerability, and preliminary anti-tumor efficacy of different combination regimens of the product in patients with recurrent ovarian cancer. Subject recruitment and screening are currently being actively advanced.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1113503019?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-31 18:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113503019","market":"sh","top_or_hot":-1,"title":"CSPC Pharmaceutical Group's SYS6041 Combination Therapy Phase II Trial for Recurrent Ovarian Cancer Has Officially Launched at the First Center in China","media":"Stock News","content":"<p><b>CSPC PHARMA</b> (01093) has announced that the Phase II clinical trial for its SYS6041 (the product) in combination therapy to treat recurrent ovarian cancer has officially launched at the first center in China. The product is an antibody-drug conjugate targeting folate receptor alpha (FRα), classified as a Class 1 therapeutic biological product.<br><br>The antibody of this product can specifically bind to the surface of cells expressing FRα and be internalized into the cells' lysosomes. There, it is specifically cleaved by cathepsins to release a small molecule toxin—a topoisomerase I inhibitor—thereby killing tumor cells. Additionally, the product can nonspecifically clear surrounding tumor cells through the bystander effect.<br><br>Previously, the company received the Phase II clinical trial approval notice for combination therapy from the National Medical Products Administration in June 2026. The clinical trial is now underway, aiming to evaluate the safety, tolerability, and preliminary anti-tumor efficacy of different combination regimens of the product in patients with recurrent ovarian cancer. Subject recruitment and screening are currently being actively advanced.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSPC Pharmaceutical Group's SYS6041 Combination Therapy Phase II Trial for Recurrent Ovarian Cancer Has Officially Launched at the First Center in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSPC Pharmaceutical Group's SYS6041 Combination Therapy Phase II Trial for Recurrent Ovarian Cancer Has Officially Launched at the First Center in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-31 18:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>CSPC PHARMA</b> (01093) has announced that the Phase II clinical trial for its SYS6041 (the product) in combination therapy to treat recurrent ovarian cancer has officially launched at the first center in China. The product is an antibody-drug conjugate targeting folate receptor alpha (FRα), classified as a Class 1 therapeutic biological product.<br><br>The antibody of this product can specifically bind to the surface of cells expressing FRα and be internalized into the cells' lysosomes. There, it is specifically cleaved by cathepsins to release a small molecule toxin—a topoisomerase I inhibitor—thereby killing tumor cells. Additionally, the product can nonspecifically clear surrounding tumor cells through the bystander effect.<br><br>Previously, the company received the Phase II clinical trial approval notice for combination therapy from the National Medical Products Administration in June 2026. The clinical trial is now underway, aiming to evaluate the safety, tolerability, and preliminary anti-tumor efficacy of different combination regimens of the product in patients with recurrent ovarian cancer. Subject recruitment and screening are currently being actively advanced.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1960683339.HKD","symbol_name":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","start_time":0,"source_url":"","article_id":"1113503019","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113503019","pubTimestamp":1785492493,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CSPC PHARMA (01093) has announced that the Phase II clinical trial for its SYS6041 (the product) in combination therapy to treat recurrent ovarian cancer has officially launched at the first center...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","LU0140636845.USD":"施罗德大中华区股票A Acc","BMED":"iShares Health Innovation Active ETF","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","KURE":"KraneShares MSCI All China Health Care Index ETF","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU1328277881.USD":"MANULIFE GF DRAGON GROWTH FUND \"AA\" (USD) INC","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","BK1191":"制药","PSYK":"PSYK ETF","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU0314109678.HKD":"MANULIFE GF DRAGON GROWTH \"AA\" (HKD) INC","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","IE0008368742.USD":"首域中国增长基金I Acc","BK1515":"抗疫概念","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","MDTX":"Corgi MediaTek 2x Daily ETF","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","BK1521":"挪威政府全球养老基金持仓","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","LU1813983027.USD":"MANULIFE GF DRAGON GROWTH \"AA\" (USD) INC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","01093":"石药集团","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","IBBQ":"Invesco Nasdaq Biotechnology ETF"},"translate_title":"石药集团针对复发性卵巢癌的SYS6041联合疗法II期试验在中国首个中心正式启动","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMED":1,"PSYK":1,"IBBQ":1,"01093":1,"MDTX":1,"IBBJ":1,"KURE":1},"content_text":"CSPC PHARMA (01093) has announced that the Phase II clinical trial for its SYS6041 (the product) in combination therapy to treat recurrent ovarian cancer has officially launched at the first center in China. The product is an antibody-drug conjugate targeting folate receptor alpha (FRα), classified as a Class 1 therapeutic biological product.The antibody of this product can specifically bind to the surface of cells expressing FRα and be internalized into the cells' lysosomes. There, it is specifically cleaved by cathepsins to release a small molecule toxin—a topoisomerase I inhibitor—thereby killing tumor cells. Additionally, the product can nonspecifically clear surrounding tumor cells through the bystander effect.Previously, the company received the Phase II clinical trial approval notice for combination therapy from the National Medical Products Administration in June 2026. The clinical trial is now underway, aiming to evaluate the safety, tolerability, and preliminary anti-tumor efficacy of different combination regimens of the product in patients with recurrent ovarian cancer. Subject recruitment and screening are currently being actively advanced.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1113503019","isCrawlerRequest":true}